Session Type
Date Time

Vaccine partial efficacy means that a vaccine does not fully prevent infection by a pathogen in every person upon every exposure, but helps reduce the overall risk of becoming infected and the social and economic burden of a disease. Therefore, it may be beneficial for global public health.

Based on clinical trials to date, an HIV vaccine is likely to be only partially efficacious. Understanding the value and potential impact of a partially efficacious HIV vaccine is of prime importance. This is within the context of a global epidemic caused by a virus exhibiting a broad genetic diversity and against a background of economic austerity characterized by stagnant funding for vaccine R&D, complex manufacturing processes, indeterminate but challenging financing mechanisms, and complex regulatory pathways to licensure and roll out. It is also critical to assess end users’ acceptability and potentially increased risk behaviours in response to a partially effective HIV vaccine, which may further subvert the effectiveness of a vaccine in controlling the HIV epidemic.

This session will introduce participants to partially effective interventions and will include a panel discussion with insight from a range of stakeholders. The discussion will be followed by a Q&A with the audience.

Partial Efficacy, from trial to population
Deborah Donnell, Fred Hutchinson Cancer Research Center, United States
Learning from experience
Willem Hanekom, Bill & Melinda Gates Foundation, United States
Panel moderated discussion
Helen Rees, Wits RHI, ECHO Committee Consortium, South Africa
Jared Baeten, University of Washington, Seattle, United States
Frank Tomaka, Janssen Research and Development, United States
Moses Supercharger Nsubuga, Stigmaless, Uganda
Carl Dieffenbach, NIH, United States
Audience Q&A